Comparative effects of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors on heart failure with preserved ejection fraction in diabetic patients: a meta-analysis
Abstract Background Heart failure with preserved ejection fraction (HFpEF) is common in type 2 diabetes mellitus (T2D), leading to high morbidity and mortality. Managing HFpEF in diabetic patients is challenging with limited treatments. Sodium-glucose co-transporter 2 (SGLT2) inhibitors and glucagon...
Main Authors: | Arif Albulushi, Desmond Boakye Tanoh, Ahmed Almustafa, Nadya Al Matrooshi, Ronald Zolty, Brian Lowes |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-08-01
|
Series: | Cardiovascular Diabetology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12933-024-02415-8 |
Similar Items
-
Sodium‐glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta‐analysis
by: Arjun K. Pandey, et al.
Published: (2022-04-01) -
Diabetes and Excess Aldosterone Promote Heart Failure With Preserved Ejection Fraction
by: Bence Hegyi, et al.
Published: (2022-12-01) -
Meta-analysis addressing the impact of sodium-glucose Co-transporter-2 inhibitors on the risk for atrial fibrillation among individuals with heart failure with preserved ejection fraction
by: Dimitrios Patoulias, et al.
Published: (2022-12-01) -
Caloric restriction and its mimetics in heart failure with preserved ejection fraction: mechanisms and therapeutic potential
by: Alexander Fuerlinger, et al.
Published: (2025-01-01) -
The role of coronary microvascular dysfunction in the pathogenesis of heart failure with preserved ejection fraction
by: Becker Al-Khayatt, et al.
Published: (2024-05-01)